Zobrazeno 1 - 10
of 208
pro vyhledávání: '"Peter J, Weiden"'
Publikováno v:
BMC Psychiatry, Vol 22, Iss 1, Pp 1-12 (2022)
Abstract Background Impaired insight poses a challenge in the treatment of patients with schizophrenia because of its potential to jeopardize therapeutic engagement and medication adherence. This study explored how insight impairment, graded from non
Externí odkaz:
https://doaj.org/article/c1a9b3d5da4e4c5fb66e9a7bbc9902b3
Autor:
Henry A. Nasrallah, Peter J. Weiden, David P. Walling, Yangchun Du, Baiyun Yao, Sergey Yagoda, Amy Claxton
Publikováno v:
BMC Psychiatry, Vol 21, Iss 1, Pp 1-13 (2021)
Abstract Background A randomized, controlled, phase 3b study (ALPINE) evaluated efficacy and safety of a 2-month formulation of aripiprazole lauroxil (AL) using a 1-day initiation regimen in patients hospitalized for an acute exacerbation of schizoph
Externí odkaz:
https://doaj.org/article/eadc67c7e7c04be7af8d394b3a87cbf9
Publikováno v:
BMC Psychiatry, Vol 21, Iss 1, Pp 1-8 (2021)
Abstract Background This post hoc analysis of clinical trial data evaluated long-term, self-reported mental and physical health-related quality of life (HRQoL) scores in schizophrenia patients receiving aripiprazole lauroxil (AL), an atypical long-ac
Externí odkaz:
https://doaj.org/article/051832cf57834389ad3adab842a2c462
Autor:
Leona Bessonova, Dawn I. Velligan, Peter J. Weiden, Amy K. O’Sullivan, Aaron Yarlas, Martha Bayliss, Nishtha Baranwal, Kaitlin Rychlec, Julia Carpenter-Conlin, Michael J. Doane, Martha Sajatovic
Publikováno v:
BMC Psychiatry, Vol 20, Iss 1, Pp 1-12 (2020)
Abstract Background Oral antipsychotic (AP) medications are frequently prescribed to people with bipolar I disorder (BD-I). A cross-sectional online survey examined the experiences of people living with BD-I with a history of recent AP use. Methods A
Externí odkaz:
https://doaj.org/article/d1a7435839cb445b821f9c5e121e9eef
Publikováno v:
Trends in Pharmacological Sciences. 43:1098-1112
Modern interest in muscarinic acetylcholine receptor (mAChR) activators for schizophrenia began in the 1990s when xanomeline, an M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63266f26f1cb0b097ede00179965f79c
https://doi.org/10.1016/j.tips.2022.09.006
https://doi.org/10.1016/j.tips.2022.09.006
Autor:
Eric Achtyes, Adam Simmons, Anna Skabeev, Nikki Levy, Ying Jiang, Patricia Marcy, Peter J. Weiden
Publikováno v:
BMC Psychiatry, Vol 18, Iss 1, Pp 1-7 (2018)
Abstract Background Despite the availability of numerous antipsychotic medications, many patients with schizophrenia continue to experience side effects that contribute to the overall burden of the illness. The present survey of patients with schizop
Externí odkaz:
https://doaj.org/article/075c84c28d3e42dea59868f6dc8626a4
Autor:
Amber Martin, Leona Bessonova, Rachel Hughes, Michael J. Doane, Amy K. O’Sullivan, Kassandra Snook, Allie Cichewicz, Peter J. Weiden, Philip D. Harvey
Publikováno v:
Advances in Therapy. 39:3933-3956
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::51d114b3dab4e0cc4cdc78a07f8a6c2a
https://doi.org/10.1007/s12325-022-02232-z
https://doi.org/10.1007/s12325-022-02232-z
Autor:
Christoph U. Correll, Angel S. Angelov, Andrew C. Miller, Peter J. Weiden, Stephen K. Brannan
Publikováno v:
Schizophrenia. 8
KarXT combines xanomeline, an M1/M4 preferring muscarinic agonist with no direct D2 receptor antagonism, with the peripherally restricted anticholinergic trospium. In EMERGENT-1 (NCT03697252), a 5-week, randomized, double-blind, placebo-controlled, p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ca2dbdc49679645a2cd92d4b9cfa76c2
https://doi.org/10.1038/s41537-022-00320-1
https://doi.org/10.1038/s41537-022-00320-1
Publikováno v:
BMC Psychiatry, Vol 21, Iss 1, Pp 1-8 (2021)
BMC Psychiatry
BMC Psychiatry
Background This post hoc analysis of clinical trial data evaluated long-term, self-reported mental and physical health-related quality of life (HRQoL) scores in schizophrenia patients receiving aripiprazole lauroxil (AL), an atypical long-acting inje
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c32caff7c4af4140f34c63f11169612e
https://doaj.org/article/051832cf57834389ad3adab842a2c462
https://doaj.org/article/051832cf57834389ad3adab842a2c462
Publikováno v:
CNS Spectrums. 27:262-267
Aripiprazole lauroxil (AL) is a long-acting atypical antipsychotic approved for the treatment of schizophrenia in adults. AL has five regimen options that offer three different injection intervals using four different dosage strengths. The relationsh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e78a29364530ace2b415fa84fcf59b3
https://doi.org/10.1017/s1092852920002072
https://doi.org/10.1017/s1092852920002072